Benzinga · Oct 22, 2026
RBC Capital Maintains Outperform on United Therapeutics, Lowers Price Target to $697
RBC Capital analyst Lisa Walter maintains United Therapeutics (NASDAQ:UTHR) with a Outperform and lowers the price target from $708 to $697.
UT
NYSE · UTHR
United Therapeutics Corporation
Healthcare · Biotechnology
$598.72
Up+$5.18 (+0.87%)
Updated Oct 31, 2026, 3:38 PM
SID Score
7.7/10
Composite research score
Smart Money
58/100
Neutral
- Market cap
- 21.83B
- P/E ratio
- 16.83
- Dividend yield
- 0.00%
- 52-week range
- $430.02 – $609.35
- Volume
- 518.24K
- Avg. volume
- 627.5K
Price performance · UTHR
UTHR price history
1M range · 0 trading sessions · Daily adjusted prices
UTHR does not have enough price history for the selected period.
Data unavailable
Market data is busy. Please try again shortly.
Latest UTHR news
The latest Smart Investors Daily articles mentioning UTHR.
Stock researchCompany · Overview
Company
Market Activity
Research & News
UTHR research
Overview
Company profile and research snapshot.
Company profile
United Therapeutics Corp specializes in drug development for pulmonary arterial hypertension (PAH), a rare and progressive disease marked by abnormally high blood pressure in the arteries of the lungs. The company's therapies for PAH largely focus on the prostacyclin pathway, and many of its treatments are based on the same molecule, treprostinil. The company markets and sells the following commercial therapies in the United States to treat PAH: Tyvaso DPI (treprostinil) Inhalation Powder, Remodulin Injection, Orenitram (treprostinil) Extended-Release Tablets, Adcirca (tadalafil) Tablets, and Unituxin. In addition, it is developing a pipeline of projects that includes new indications and delivery devices for existing products and new products to treat PAH and other conditions.
Visit company websiteAnalyst outlook
Consensus and target data currently published for this company.
- Consensus
- Buy
- Average target
- $539.83
- Implied upside
- —
- Analysts
- 21
| Date | Firm | Rating | Target |
|---|---|---|---|
| Oct 28, 2026 | JP Morgan | Overweight | — |
| Oct 22, 2026 | RBC Capital | Outperform | — |
| Oct 19, 2026 | Leerink Partners | Outperform | — |
| Oct 8, 2026 | RBC Capital | Outperform | — |
| Oct 7, 2026 | Morgan Stanley | Equal-Weight | — |
News briefing
No generated briefing is available yet.
Yahoo · Oct 22, 2026
United Therapeutics Corporation Announces Additional $2 Billion Share Repurchase Authorization
SILVER SPRING, M.D. & RESEARCH TRIANGLE PARK, N.C., October 22, 2026--United Therapeutics Corporation (Nasdaq: UTHR), a public benefit corporation, announced today that the company’s Board of Directors has authorized a new share repurchase program for up to $2 billion of the company’s common stock, available through October 21, 2027.
Yahoo · Oct 21, 2026
United Therapeutics Corporation to Report Third Quarter 2026 Financial Results Before Market Open on Wednesday, November 4, 2026
SILVER SPRING, Md. & RESEARCH TRIANGLE PARK, N.C., October 21, 2026--United Therapeutics Corporation (Nasdaq: UTHR) announced today that it will report its third quarter 2026 financial results in a press release that will be issued on Wednesday, November 4, 2026, at approximately 6:30 a.m. Eastern Time.
Yahoo · Oct 20, 2026
United Therapeutics (UTHR): Can the Profit-Machine Biotech Finally Crack the S&P 500?
United Therapeutics Corporation (NASDAQ:UTHR) develops treatments for pulmonary arterial hypertension, a rare and dangerous high blood pressure in the lungs, with its Tyvaso franchise at the core. At about $23.5 billion in market value, it is one of the steadiest earners in biotech, and that is the whole point for index purposes. Most drug developers […]
AI research layers
Interpretive context generated from the platform’s current data sources.
No results
AI research layers have not been published yet.
